Nidec Sankyo

Daiichi Sankyo’s SANTORINI Study Gets Underway, Investigating Cholesterol Care Across Europe

Retrieved on: 
Wednesday, June 10, 2020

The SANTORINI study will provide important insights into how patients are currently being managed and the effectiveness of the treatments they are receiving.

Key Points: 
  • The SANTORINI study will provide important insights into how patients are currently being managed and the effectiveness of the treatments they are receiving.
  • Daiichi Sankyo has been working closely with SANTORINI trial sites to ensure we follow local recommendations to progress the study in the most effective and safest way possible, said Dr. Inaam Haq, Medical Affairs Director, Antithrombotic & Cardiovascular at Daiichi Sankyo Europe.
  • The SANTORINI study is a multinational, prospective, observational study that will enrol 8,000 patients from 800 sites in 14 countries across Europe.
  • Daiichi Sankyo Europe has licensed exclusive commercialisation rights to these products in the European Economic Area and Switzerland from Esperion.

Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan

Retrieved on: 
Monday, May 13, 2019

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (Daiichi Sankyo) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (Daiichi Sankyo) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.
  • With Daiichi Sankyos first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under the terms of the companies collaboration agreement.
  • Daiichi Sankyos launch of MINNEBRO in Japan is an important advance for patients with hypertension in Japan, as well as for our two companies, said Michael M. Morrissey, Ph.D., President and Chief Executive Officer of Exelixis.
  • MINNEBRO is a novel mineralocorticoid receptor blocker identified during the prior research collaboration between Exelixis and Daiichi Sankyo and subsequently developed and commercialized by Daiichi Sankyo.